Invivo therapeutics announces completion of enrollment for the inspire 2.0 acute spinal cord injury study

Cambridge, mass.--(business wire)--invivo therapeutics holdings corp. (nasdaq: nviv), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has completed enrollment in the inspire 2.0 study for patients with acute spinal cord injury. the 20-patient study is a randomized, controlled trial featuring 10 subjects in each study arm, designed to enhance the existing clinical evidence for the neuro-spinal sca
NVIV Ratings Summary
NVIV Quant Ranking